Eli Lilly and Novo Nordisk Compete in the Growing Obesity Drug Market
The obesity drug market is currently dominated by two major players: Eli Lilly and Novo Nordisk. Both companies are working […]
Pharmaceutical News
Pharmaceutical Companies Face Major Challenges as Cancer Drug Patents Expire Soon
Over the next five years, many top-selling cancer drugs from major pharmaceutical companies will lose their patent protection. This is
Health Leaders Consider Tighter Rules on Drug Ads Aimed at Consumers
A report from the Make America Healthy Again (MAHA) Commission was delayed earlier this month, but leaked documents reveal plans
New Efforts to Improve Cancer Treatment Decisions with Better Data
Measuring how long a cancer treatment extends life (overall survival, or OS) is the best way to judge its effectiveness.
FDA Gives Fast-Track Status to New Lung Cancer Treatment
The US Food and Drug Administration (FDA) has given special recognition to a new experimental drug called izalontamab brengitecan (iza-bren).
Pharmaceutical News
Gilead’s Kite to Buy Interius BioTherapeutics for $350 Million to Advance Next-Gen Cancer Treatments
Gilead’s Kite Pharma has agreed to purchase Interius BioTherapeutics for $350 million. This deal will help Kite expand its work
Pharmaceutical News
Eli Lilly’s Neuroscience Leader Anne White to Retire After 30 Years
Anne White, the Executive Vice President and President of Lilly Neuroscience at Eli Lilly and Company, will retire at the
Eli Lilly Seeks New Neuroscience Leader as Longtime Executive Anne White Retires
Eli Lilly is looking for a new leader for its neuroscience division after announcing that Anne White, the current head,
New Blood Test Could Replace Tissue Biopsies for Cancer Patients
In this project, ANGLE’s research team will use the Parsortix system to collect cancer cells from the blood of cancer
Pharmaceutical News
Johnson & Johnson Invests $2 Billion to Expand US Drug Manufacturing with Fujifilm
Johnson & Johnson (J&J) has made a major move to strengthen its US manufacturing operations by signing a $2 billion,